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The pharmacokinetics and pharmacodynamics of oral S-1, a dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine,
were compared with those of protracted venous infusion (PVI) of 5-fluorouracil (5-FU). In all, 10 patients with gastric cancer received
PVI of 5-FU at a dose of 250mgm
 2day
 1 for 5 days. After a washout period of 9 days, the patients received two divided doses daily
for 28 days. S-1 was administered orally at about 0900 and 1900 hours. The daily dose of S-1 in terms of tegafur was 80mgday
 1 in
patients with a body surface area (BSA) of o1.25m
2, 100mgday
 1 in those with a BSA of X1.25m
2 to o1.5m
2, and 120mgday
 1
in those with a BSA of X1.5m
2. Plasma concentrations of 5-FU and F-b-alanine (FBAL) were measured for pharmacokinetic analysis,
and the plasma uracil concentration was monitored as a surrogate marker of DPD inhibition (pharmacodynamic analysis) in the same
patients on days 1–5 of PVI of 5-FU and on days 1–5 of oral S-1. The area under the curve (AUC0–10h) of 5-FU on day 5 was
7287113nghml
 1 for PVI of 5-FU and 13647374nghml
 1 for S-1. The median 5-FU PVI:S-1 ratio of the AUC0–10hof 5-FU was
1.9. The AUC0–10hof FBAL on day 5 of PVI of 5-FU was 946573225nghml
 1, AUC0–10h, as compared with 17257605nghml
 1
on day 5 of S-1 treatment. The AUC0–10hof uracil on day 5 was 252760nghml
 1 with PVI of 5-FU and 1258273060nghml
 1
with S-1. The AUC0–10hof FBAL was markedly lower and plasma uracil concentrations were significantly higher for S-1 than for PVI
of 5-FU, clearly demonstrating the effect of DPD inhibition.
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Continuous protracted intravenous infusion (PVI) of 5-fluorour-
acil (5-FU) has a higher response rate, less frequent haematologic
toxicity (mainly neutropenia), and more frequent hand–foot
syndrome (HFS) than bolus injection of 5-FU in patients with
metastatic colorectal cancer (The Meta-Analysis Group in Cancer,
1998). Hand–foot syndrome and stomatitis each occur in about
23% of patients given 5-FU by PVI, whereas grade 3 leukopenia
develops in only 1%. Most patients who receive 5-FU by PVI have
no severe toxicity; the dose-limiting toxicity (DLT) is HFS (Lokich
et al, 1989). Previous clinical trials have shown that PVI of 5-FU is
one of the most effective and safest regimens. However, PVI
requires a central venous catheter as well as an ambulatory pump,
which is expensive and may lead to complications, and adversely
affect patients’ quality of life.
Oral fluoropyrimidine derivatives have been developed to
circumvent the problems associated with PVI of 5-FU. S-1 is one
such derivative that combines tegafur with two modulators of 5-FU
metabolism, 5-chloro-2,4-dihydroxypyridine (CDHP), a reversible
inhibitor of dihydropyrimidine dehydrogenase (DPD), and potas-
sium oxonate, in a molar ratio of 1:0.4:1. Tegafur, an oral
prodrug of 5-FU, is gradually converted to 5-FU and rapidly
metabolised by DPD in the liver. The DPD-inhibitory activity of
CDHP is 180-fold higher than that of uracil, confirmed to be an
effective DPD inhibitor in the form of uracil/tegafur (UFT) in vitro.
Potassium oxonate is an orotate phosphoribosyl transferase
inhibitor that is distributed primarily to the gastrointestinal tract.
This component of S-1 decreases the incorporation of 5-
fluorouridine triphosphate into RNA in the gastrointestinal
mucosa and reduces the incidence of diarrhoea.
F-b-alanine (FBAL) is a main metabolite of 5-FU. F-b-alanine
and fluorocitrate are thought to cause the cardiotoxic and
neurotoxic effects of 5-FU by inhibiting the tricarboxylic acid
cycle (Koenig and Patel, 1970; Okeda et al, 1990; Robben et al,
1993; Diasio, 1998; Kuwata et al, 2000; Kato et al, 2001). The CDHP
component of S-1 inhibits DPD, the rate-limiting enzyme in the
catabolic pathway of 5-FU. Consequently, the plasma FBAL
concentration after oral administration of S-1 is significantly
lower than that after PVI of 5-FU. However, information on plasma
FBAL concentrations in patients given 5-FU remains scant (Van
Kuilenberg et al, 2001).
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lThe objectives of this study were to investigate differences in
pharmacokinetics (PK) and pharmacodynamics (PD) between oral
S-1 and PVI of 5-FU and to examine the DPD inhibitory activity of
S-1.
MATERIALS AND METHODS
Anticancer drugs
S-1 capsules combining tegafur, CDHP, and potassium oxonate in
a molar ratio of 1:0. 4:1 (Taiho Pharmaceutical Co. Ltd., Tokyo,
Japan) were used. Each capsule contained 20 or 25mg of tegafur. 5-
fluorouracil was obtained from Kyowa Hakko Co., Ltd. (Tokyo,
Japan).
Patients
In all, 10 consecutive patients with histologically proven metastatic
gastrointestinal cancer were enrolled into this pharmacokinetic
study. All patients were between 20 and 75 years of age and had an
Eastern Cooperative Group (ECOG) performance status of 0–2,
adequate baseline bone marrow (WBC count 3500ml
 1 or more
and platelet 100000ml
 1 or more, hepatic (serum bilirubin level
1.5mgdl
 1 or less, and serum GOT and GPT 40Ul
 1 or less), and
renal (serum creatinine level 1.2mgdl
 1 or less) function, and a
life expectancy of at least 12 weeks.
Patients were excluded if they had symptomatic brain metastasis
or other serious concurrent disease. This study was approved by
the institutional review board of the National Cancer Center
Hospital. Written informed consent was obtained from each
patient before enrolment.
Study design
All 10 patients received 5-FU by PVI at a rate of 250mgm
 2day
 1
via a peripheral vein. Infusion was carried out with the use of a
battery-operated pump (STC-508, Terumo Co., Ltd., Tokyo, Japan)
for five consecutive days. The assigned daily dose of 5-FU was
diluted in 500ml of normal saline for infusion. After a washout
period of 9 days, patients received S-1 in two divided doses daily
for 28 consecutive days. S-1 was administered orally within 1h
after breakfast and supper, at about 0900 and 1900 hours The daily
dose of S-1 in terms of tegafur was 80mgday
 1 in patients with a
body surface area (BSA) of o1.25m
2, 100mgday
 1 in those with a
BSA of X1.25m
2 to o1.5m
2, and 120mgday
 1 in those with a
BSA of X1.5m
2.
Blood and urine sample collection
On days 1 and 5 of 5-FU PVI, blood samples were taken at 0
(before administration), 2, 6, and 10h after the start of the infusion
(0900 hours in all patients). On days 2–4, one blood sample was
obtained at 0900 hours before the start of the next 24-h cycle.
During oral administration of S-1, blood samples were taken on
day 1 before the first dose of the day and at 1, 2, 4, 6, and 10h. On
days 2–4 of S-1 treatment, blood samples were taken before
administration in the morning and at 4 and 10h. On day 5, blood
samples were obtained at 0, 2, 4, and 10h. Peripheral blood
samples (6ml per sampling time) were collected in heparinised
tubes and centrifuged at 1000g for 15min at 41C. The plasma was
stored at  201C until analysis. Urine was collected from 0 to 24h
after the start of drug administration on day 1 of each treatment
and refrigerated during the collection period.
Assay of 5-FU, uracil, and FBAL
Analysis of 5-FU and uracil was carried out as described by
Matsushima et al (1997), with minor modification. 5-Fluorouracil
and uracil were extracted with ethyl acetate after washing with
dichloromethane and were subjected to a reaction to induce their
trimethylsilyl derivatives. 5-Fluorouracil and uracil were analysed
by electron impact ionisation gas-chromatography/mass-spectro-
metry (GC–MS). For analysis of 5-FU by GC–MS, stable isotopes
were used as internal standards. The measurable ranges of plasma
or urine levels were 1–400ngml
 1 for 5-FU and 5–2000ngml
 1
for uracil. For analysis of FBAL, plasma was deproteinised with
ethanol and washed with dichloromethane. F-b-alanine was treated
with 2,4-dinitrofluorobenzene to derive its dinitrophenyl ester, and
the reaction product was extracted with dichloromethane under
acidic conditions. The reaction product was separated by high-
pressure liquid chromatography (LC) with a reversed-phase
column, and LC/tandem-mass spectrometry was performed with
the use of negative ion-electron spray ionisation. DL-norvaline was
used as an internal standard. The measurable range of plasma or
urine levels was 5–2000ngml
 1 for FBAL.
Pharmacokinetics
Maximum plasma concentrations (Cmax) were determined from
the observed highest concentration after treatment with PVI of
5-FU or oral S-1. The area under the curve (AUC) was calculated
from 0 to 10h (AUC0–10h) on days 1 and 5 of each treatment
according to the trapezoidal rule, using a WinNonlin program
(Ver. 3.1, Pharsight Co., Mountain View, CA, USA). The same
program was used to simulate plasma 5-FU concentrations during
treatment with S-1. AUCs were calculated on the basis of data
obtained at the following time points; 0, 1, 2, 4, 6, and 10h for S-1
on day 1; 0, 2, 4, and 10h for S-1 on day 5; and 0, 2, 6, and 10h for
PVI of 5-FU on days 1 and 5.
DPD activity
DPD activity was determined by a catalytic assay as described by
Ikenaka et al (1979). Blood samples were collected from patients
before the start of 5-FU PVI, at about 0900 hours. Peripheral blood
mononuclear cells (PBMC) prepared from about 10ml of blood
were thawed and placed in 250ml of a homogenised buffer
containing 10mM Tris-HCl, 1mM EDTA, and 0.5mM dithiothreitol,
pH 7.4. The PBMCs were then homogenised by sonication, and the
homogenate was centrifuged at 105000g for 60min (41C). The
supernatant fraction was collected as the enzyme source and was
frozen and stored at  801C until analysis.
RESULTS
Between April and October 2000, 10 male patients were enrolled.
Their median age was 66 years (range, 45–75 years). All 10
patients had metastatic gastric carcinoma and eight had undergone
gastrectomy. Two patients had previously received chemotherapy
(irinotecan plus mitomycinC in 1, and cisplatin plus irinotecan in
the other). The median body surface area (BSA) was 1.52m
2
(range, 1.38–1.85m
2). The initial doses of S-1 were
100mgbody
 1day
 1 in four patients and 120mgbody
 1day
 1 in
six patients. The median actual dose of S-1 in the 10 patients was
71.6mgm
 2day
 1 (range, 64.8–80.0mgm
 2day
 1) (Table 1).
5-FU, uracil, and FBAL PK
The plasma concentrations of 5-FU, uracil, and FBAL after
administration of PVI 5-FU and oral S-1 in the 10 patients on
days 1–5 are shown in Figures 1 and 2. The plasma 5-FU
concentration reached a steady state 2h after the start of PVI. This
steady state was maintained throughout the 5 days. During
treatment with S-1, the time to the peak plasma concentration of
5-FU was 2–4h. The Cmax of 5-FU after S-1 treatment on day 1 was
Pharmacokinetics after intravenous 5-FU and oral S-1
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llower than the Cmax of 5-FU on days 2–5 of S-1 treatment. The
plasma concentration of uracil during S-1 treatment was higher
than the baseline value.
The Cmax and AUC0–10hof 5-FU in plasma during S-1 treatment
were higher than the steady-state concentration and AUC0–10h
of 5-FU in plasma during PVI of 5-FU. On day 5, the median
AUC0–10hand Cmax of 5-FU with S-1 were 1.9- and 2.5-fold greater
than the respective values with PVI of 5-FU.
The plasma FBAL concentration during S-1 treatment was
markedly lower than that during PVI of 5-FU. On day 5, the
AUC0–10hof FBAL with PVI of 5-FU was 5.5-fold greater than that
with S-1.
On day 1 of PVI of 5-FU, 1.270.7% (range, 0.3–2.3%) and
39.2711.3% (range, 15.9–52.9%) of the administered dose was
excreted in urine as 5-FU and FBAL, respectively. On day 1 of
treatment with oral S-1, 7.372.2% (range, 3.9–11.0%) and
21.776.6% (range, 13.0–35.0%) of the administered dose were
excreted in urine as 5-FU and FBAL, respectively.
The mean DPD activity of PBMC was 226pmolmin
 1mg
 1
(range, 128–492pmolmin
 1mg
 1). There was no correlation
between the DPD activity of PBMC and the plasma concentration
or AUC0–10h of 5-FU.
DISCUSSION
This study showed that the Cmax and AUC0–10h of 5-FU during
treatment with oral S-1, given at dose levels recommended on the
basis of phase I and II trials, were about two times greater than the
respective values during PVI of 5-FU. Our results suggest that the
higher incidence of leukopenia and diarrhoea associated with S-1,
as compared with PVI of 5-FU, may be attributed to the
significantly higher Cmax and AUC of plasma 5-FU (Thyss et al,
1986; Vokes et al, 1996; Van Groeningen et al, 2000). In the phase I
trial with once daily administration schedule of S-1, pharmaco-
dynamic analysis demonstrated a correlation between grade of
diarrhoea and both Cmax of 5-FU (r¼0.57, Po0.05) and AUC of
5-FU (r¼0.74, Po0.01) (Cohen et al, 2002).
The plasma concentration of FBAL, the main catabolite of 5-FU,
was significantly lower during S-1 treatment than during PVI of
Table 1 Pharmacokinetic parameters of 5-FU, uracil, and FBAL in 10 patients receiving PVI and S-1
5-FU Uracil FBAL
Day 1 Day 5 Day 1 Day 5 Day 1 Day 5
Cmax (ngml
 1)
PVI 93724 93713 24773 0 79 858713 11577350
S-1 144733 230769 12627355 15597409 100769 198774
P-value
a 0.004 o0.001 o0.001 o0.001 o0.001 o0.001
AUC (nghrml
 1)
PVI 7337164 7287113 200760 252760 62677113 946573225
S-1 8577209 13647374 903372176 1258273060 7677395 17257605
P-value
a 0.181 o0.001 o0.001 o0.001 o0.001 o0.001
FBAL¼F-b-alanine.
aPaired t-test.
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Figure 1 Plasma concentrations of 5-FU and uracil vs time after PVI of 5-
FU and after oral S-1. Closed and open circles show the concentration of 5-
FU and concentration of uracil, respectively. The left and right graphs show
data for PVI of 5-FU and for S-1, respectively. Data are presented as means;
bars, s.d.
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Figure 2 Plasma concentration of FBAL vs time after PVI of 5-FU and
after oral S-1. Closed and open circles show the plasma concentration of
FBAL after S-1 and PVI of 5-FU, respectively. Data are presented as means;
bars, s.d.
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l5-FU. The AUC0–10hof the plasma FBAL concentration on day 5 of
PVI of 5-FU was five-fold higher than that on day 5 of treatment
with S-1. The plasma uracil concentration increased during S-1
treatment. The Cmax of uracil was attained 4h after oral
administration of S-1 and decreased at 10h. These results provide
evidence that CDHP reversibly inhibits DPD. Plasma levels of
FBAL and uracil have also been measured in European phase I
studies of S-1. Very low levels of FBAL were detected because of
DPD inhibition in 4 patients given S-1 (Van Kuilenberg et al,
2001). This low level of FBAL in plasma may be responsible for the
decreased incidence of neurotoxicity and cardiotoxicity associated
with 5-FU. In fact, several phase I and II clinical trials of S-1 have
reported no cardiotoxicity or neurotoxicity (Taguchi et al, 1997;
Sakata et al, 1998; Sugimachi et al, 1999; Koizumi et al, 2000; Ohtsu
et al, 2000; Cohen et al, 2002; Chollet et al, 2003; Hoff et al, 2003;
Van den Brande et al, 2003).
Capecitabine is also an oral fluoropyrimidine derivative (Bud-
man et al, 1998). When capecitabine was administered orally after
meals at a dose of 1255mgm
 2, the AUC of the plasma FBAL
concentration was 31400nghml
 1Reigner et al, 1998). This is 3.4-
fold greater than the AUC of FBAL during PVI of 5-FU and 18-fold
higher than that during treatment with oral S-1. The AUC of
plasma 5-FU after treatment with capecitabine was 698nghrml
 1,
and the Cmax of plasma 5-FU was 310ngml
 1. The AUC of 5-FU
was similar to that during PVI of 5-FU and about half that during
treatment with S-1. The Cmax of 5-FU was 3.3-fold higher than that
during PVI of 5-FU and 1.3-fold higher than that during S-1
treatment. Thus, the AUC of the plasma FBAL concentration after
oral capecitabine was much higher than that after oral S-1. In a
randomised phase II trial of capecitabine in patients with
metastatic colorectal cancer, the incidence of cardiotoxicity was
5% (five out of 108) (Van Cutsem et al, 2000). The treatment was
discontinued in four patients because of chest pain, angina, or
atrial fibrillation. Paresthesia occurred in 12% of the patients (Van
Cutsem et al, 2000). The incidence of neurotoxicity was high, as
compared with that during PVI of 5-FU or during treatment with
S-1.
Capecitabine is associated with a high incidence of HFS,
occurring in 45% of patients (Van Cutsem et al, 2000). The
incidence of grade 3 HFS is 15–18% (Van Cutsem et al, 2000, 2001;
Hoff et al, 2001). Hand–foot syndrome is also a major problem
during PVI of 5-FU with a reported incidence of about 23%
(Lokich et al, 1989). S-1 has a very low incidence of HFS (Taguchi
et al, 1997; Sakata et al, 1998; Sugimachi et al, 1999; Koizumi et al,
2000; Ohtsu et al, 2000; Van Groeningen et al, 2000; Cohen et al,
2002; Hoff et al, 2003; Peters et al, 2003). Hand–foot syndrome has
been observed in just eight out of 3808 mainly Asian patients
(0.2%) treated with S-1, according to the safety database of the
manufacturer of this compound, Taiho Pharmaceuticals. In
addition, HFS occurred in 9–10% in European phase II trial;
however, most of the cases were limited to grade 1–2 (Chollet
et al, 2003; Van den Brande et al, 2003). Interestingly, a low
incidence of HFS has also been reported for eniluracil, an
irreversible DPD inhibitor, plus oral 5-FU (Mani et al, 2000). Only
two of 55 patients (4%) treated with oral 5-FU plus eniluracil had
mild HFS. These findings suggest that the degree of DPD inhibition
may correlate with the frequency and grade of HFS. Although the
mechanism of HFS remains unknown, it may occur secondarily to
the formation of 5-FU catabolites. Owing to modulation at the DPD
level, 5-FU catabolites are less likely to form during treatment with
S-1 and oral 5-FU plus eniluracil, as compared with capecitabine.
However, we have no direct evidence showing that FBAL causes
HFS.
In conclusion, we found that oral S-1 at presently recommended
doses produced a higher Cmax and a greater AUC of plasma 5-FU
than did PVI of 5-FU, with no elevation of the plasma FBAL
concentration. During S-1 treatment, DPD inhibition by CDHP
apparently resulted in lower plasma FBAL concentrations and
higher plasma uracil concentrations than did PVI of 5-FU.
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